This retrospective, nonrandomized analysis evaluated the effect of initiating statin or beta-blocker treatment early in the course of heart failure developed during acute myocardial infarction compared with the effect of neither or both treatments. Early initiation of statins or beta blockers alone was associated with improved event-free survival, and the benefits of the combined treatment were additive.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.amjcard.2003.11.027 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preventing, identifying and managing myocardial injury after non cardiac surgery - a narrative review.
Curr Opin Anaesthesiol
February 2025
Center for OUTCOMES RESEARCH and Department of Anesthesiology, UTHealth, Houston, Texas.
Purpose Of Review: There is mounting and convincing evidence that patients with postoperative troponin elevation, with or without any clinical symptoms, are at higher risk for both, short- and long-term morbidity and mortality. Myocardial injury after noncardiac surgery (MINS) is a relatively newly described syndrome, and the pathogenesis is not fully understood yet. MINS is now an established syndrome and multiple guidelines address potential etiologies, triggers, as well as preventive and management strategies.
View Article and Find Full Text PDFChange in Systemic Medication and its Influence on Intraocular Pressure - Results From the Gutenberg Health Study.
Invest Ophthalmol Vis Sci
December 2024
Department of Ophthalmology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
Article Synopsis
- This study aimed to explore how changes in systemic medication relate to intraocular pressure (IOP) in a large population in Germany.
- Researchers analyzed data from the Gutenberg Health Study, measuring IOP and recording medication changes over a five-year period in thousands of participants.
- Results showed that starting selective beta-blockers reduced IOP, while stopping them increased it; other medications' effects on IOP appeared linked to accompanying drugs or blood pressure changes.
Optimal duration of medical therapy for patients with acute myocardial infarction.
Medicine (Baltimore)
November 2024
Department of Internal Medicine, Chonnam National University Hospital, Gwangju, Republic of Korea.
Article Synopsis
- The study analyzes the impact of optimal medical therapy, including Beta-blockers, RAS inhibitors, and statins, on patients who survived an acute myocardial infarction, revealing benefits in reducing cardiac mortality.
- During a follow-up of up to 2 years, RAS inhibitors and statins prescribed at 1-year showed a significant association with lower cardiac mortality, while Beta-blockers were only effective for the first year.
- Beyond 2 years, none of these medications demonstrated a significant impact on cardiac mortality, suggesting that their effectiveness diminishes over time.
Epidemiology of ischaemic heart disease in France.
Arch Cardiovasc Dis
December 2024
Santé Publique France, 94410 Saint-Maurice, France.
Article Synopsis
- - In 2022, France recorded 242,227 hospitalizations due to ischaemic heart disease (IHD), affecting 5.6% of the adult population, with a significant mortality rate of 4.8% of all deaths being IHD-related.
- - Patients hospitalized for IHD had an average age of 69.3 years, with 29% being women; there was a high prevalence of cardiovascular risk factors, and many underwent interventions like percutaneous coronary interventions.
- - One year post-hospitalization, 29.9% of patients were rehospitalized for IHD, and 9.3% died from all causes, highlighting the need for improved prevention strategies for IHD in France.*
The Impact of Concomitant Medications on the Overall Survival of Patients Treated with Systemic Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
Clin Genitourin Cancer
December 2024
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Semmelweis University, Budapest, Hungary; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czechia; Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Research Center for Evidence Medicine, Urology Department Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address:
Article Synopsis
- Immune checkpoint inhibitors (ICI) and tyrosine kinase inhibitors (TKI) are standard treatments for advanced renal cell carcinoma, but the impact of other medications taken alongside these treatments is uncertain.
- A review of 22 studies involving over 16,000 patients found that certain concomitant medications like proton pump inhibitors and antibiotics negatively affect overall survival when taken with ICIs, while statins, renin-angiotensin system inhibitors, and beta-blockers improve survival when combined with TKIs.
- Clinicians should evaluate patients' baseline medications before starting systemic therapy for metastatic RCC, as some drugs can either reduce or enhance the effectiveness of cancer treatments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!